Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years
Journal of the American Heart Association · 21.01.2025 · 14 (2)
DOI: 10.1161/jaha.124.037639 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 21.01.2025. Verfasst von Daniele Massera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hypertrophic Cardiomyopathy Program Leon H. Charney Division of Cardiology, NYU Langone Health New York NY USA. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Cardiomyopathy, Hypertrophic, Disopyramide, Ventricular Outflow Obstruction. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive patients with symptomatic obstructive HCM with peak left ventricular outflow tract gradients of ≥30 mm Hg at rest or with provocation who were maintained on disopyramide for ≥5 years at 2 dedicated HCM centers were included: 92 patients; mean age, 62.5 years; 54% women; treated with disopyramide for median 7.2 years (left ventricular wall thickness 18±4 mm; median peak outflow gradient 95 mm Hg). At last follow‐up, 62 (67%) patients continued disopyramide, including 57 with symptom improvement ≥1 New York Heart Association class. The other 30 (33%) patients discontinued disopyramide due primarily to incomplete symptom resolution and required surgical myectomy or alcohol septal ablation (n=23) at 7.4 years from initiation. With disopyramide, resting left ventricular outflow gradients were reduced by 37% (to median 19 mm Hg), and provoked gradients decreased by 57% (to median 41 mm Hg), with no residual outflow obstruction (5 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hypertrophic Cardiomyopathy Program Leon H. Charney Division of Cardiology, NYU Langone Health New York NY USA.
- Hypertrophic Cardiomyopathy Center Lahey Hospital and Medical Center Burlington MA USA.
ORCID-Profile: Daniele Massera, Mark V Sherrid, Elizabeth Adlestein, Maria C Reuter, Martin S Maron, Barry J Maron, Ethan J Rowin
Zitieren
APA
Massera, D., Sherrid, M. V., Adlestein, E., Bokhari, N., Alvarez, I. C., Wu, W. Y., Reuter, M. C., Maron, M. S., Maron, B. J., & Rowin, E. J. (2025). Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years. Journal of the American Heart Association, 14(2). https://doi.org/10.1161/jaha.124.037639
Vancouver
Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, et al. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years. Journal of the American Heart Association. 2025;14(2). doi:10.1161/jaha.124.037639
BibTeX
@article{Massera2025,
author = {Massera, Daniele and Sherrid, Mark V and Adlestein, Elizabeth and Bokhari, Nadia and Alvarez, Isabel C and Wu, Woon Y and Reuter, Maria C and Maron, Martin S and Maron, Barry J and Rowin, Ethan J},
title = {Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {2},
doi = {10.1161/jaha.124.037639}
}
EUVIMED